BRISBANE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- InterMune, Inc. will host a conference call tomorrow, October 17, at 8:30 a.m. ET to discuss its partnership with Roche to collaborate on the research, development and commercialization of hepatitis C protease inhibitors. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or +1-706-634-0154 (international), and entering conference ID# 8455308. A replay of the webcast and teleconference will be available approximately three hours after the call.
To access the webcast, please log on to the InterMune website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The teleconference replay will be available for ten business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or +1-706-645-9291 (international) and entering the conference ID# 8455308. The webcast will be temporarily available on the company's website.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes two Phase III programs evaluating possible therapeutic candidates for treatment of patients with IPF. The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the lead HCV protease inhibitor compound, ITMN- 191, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com .
Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to anticipated future financial results and product development. All forward- looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading 'Risk Factors' in InterMune's annual report on Form 10-K filed with the SEC on March 13, 2006 (the "Form 10-K") and updates included in the most recent Form 10-Q filed with the SEC on August 8, 2006 (the "Form 10-Q"), and other periodic reports filed with the SEC.
InterMune, Inc.CONTACT: investors, InterMune, Inc. Investor Relations Dept,+1-415-466-2242, ir@intermune.com; or media, Pam Lord, of Porter NovelliLife Sciences, +1-619-849-6003, plord@pnlifesciences.com, for InterMune,Inc.
Web site: http://www.intermune.com/
